About this Research Topic
Oncolytic virus therapy for solid tumor is an well-established concept as a promising tumor treatment strategy. Oncolytic viruses are a group of naturally occurring or genetically engineered viruses that can replicate and destroy tumor cells rather than normal cells. The lysis of tumor cells effectively releases Pathogen-associated molecular patterns (PAMPs) of virus, molecular pattern signals , cytokines and so on, enhances the maturation of antigen-presenting cells (APCs), and activates antigen-specific T cells (such as CD8+ T cell) responses. These reactions initiate potent antitumor responses and mediate tumor regression at distant tumor sites not exposed to the virus.
In 2015, , the U.S. Food and Drug Administration (FDA) announced the first FDA-approved OV therapy, for the treatment of melanoma lesions in the skin and lymph nodes. OVs have been used as single agent therapy or in combination with conventional cancer therapies. Current challenges including both scientific and regulatory do not diminish the significant potential for solid tumor. There are still some questions about virus selection, virus dosage, and optimal route of virus administration.
This research topic aims to track the latest advances in oncolytic virotherapy in solid tumors (including non-small cell lung cancer, gastric cancer, breast cancer, colorectal tumor, hepatic carcinoma, etc.), with particular roles to the alteration of both the immune microenvironment and immune cells induced by oncolytic virotherapy,
Additionally, try to find novel oncolytic virus or other combined therapy to further improve safety and efficacy of oncolytic virotherapy.
Engineering oncolytic viruses to stimulate anti-tumor immune responses more effectively.
Appropriate animal models for validation of immune alterations in oncolytic virotherapy.
Novel Delivery Systems for Immunotherapy
Combination therapy with oncolytic viruses and other immunotherapies in solid tumors.
Combination therapy with oncolytic viruses and other adjuvant therapies (chemotherapy, radiotherapy, electric field therapy, conventional medical treatment, etc.) in solid tumors.
Clinical study of oncolytic virotherapy
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In 2015, , the U.S. Food and Drug Administration (FDA) announced the first FDA-approved OV therapy, for the treatment of melanoma lesions in the skin and lymph nodes. OVs have been used as single agent therapy or in combination with conventional cancer therapies. Current challenges including both scientific and regulatory do not diminish the significant potential for solid tumor. There are still some questions about virus selection, virus dosage, and optimal route of virus administration.
This research topic aims to track the latest advances in oncolytic virotherapy in solid tumors (including non-small cell lung cancer, gastric cancer, breast cancer, colorectal tumor, hepatic carcinoma, etc.), with particular roles to the alteration of both the immune microenvironment and immune cells induced by oncolytic virotherapy,
Additionally, try to find novel oncolytic virus or other combined therapy to further improve safety and efficacy of oncolytic virotherapy.
Engineering oncolytic viruses to stimulate anti-tumor immune responses more effectively.
Appropriate animal models for validation of immune alterations in oncolytic virotherapy.
Novel Delivery Systems for Immunotherapy
Combination therapy with oncolytic viruses and other immunotherapies in solid tumors.
Combination therapy with oncolytic viruses and other adjuvant therapies (chemotherapy, radiotherapy, electric field therapy, conventional medical treatment, etc.) in solid tumors.
Clinical study of oncolytic virotherapy
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: oncolytic virus, therapy, solid tumor, Combination therapeutics, immune cells, delivery system, engineered virus
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
